<DOC>
	<DOCNO>NCT02882191</DOCNO>
	<brief_summary>To evaluate effectiveness , device placement , safety , tolerability LevoCept support commence Phase III Clinical Study</brief_summary>
	<brief_title>Evaluation Efficacy Safety LevoCept</brief_title>
	<detailed_description>Study Design : Prospective , multi-center , single-arm , open-label , Phase II clinical study 250 subject enrol unto 14 center US . Study Population : Pre-menopausal woman age 18 - 40 , risk pregnancy , interested use intrauterine contraceptive birth control eligible study . Subjects must provide write informed consent meet study subject selection criterion without exclusion outline Clinical Investigation Plan ( CIP ) . Primary Effectiveness Outcome : The primary outcome measure effectiveness , evaluate absence pregnancy 12 month . Safety outcome measure include : Study Device Placement : - Ease placement - Placement success Safety : - Serious Adverse Events - Adverse Events Tolerability : - Bleeding spot pattern - Discontinuation rate reason discontinuation</detailed_description>
	<mesh_term>Levonorgestrel</mesh_term>
	<criteria>1 . Between 1840 year age time study initiation ; 1.1 Enrollment target 225 subject age 1835 ( safety effectiveness analysis ) additional 25 subject age 3640 ( safety ) ( note : subject include analysis device placement tolerability ) ; 2 . Premenopausal , determine regular menstrual cycle ( 28 ± 7 day ) last 3 month ; 2.1 Based patient history , hormonal contraceptive ; 3 . Sexually active male partner vasectomy ; 4 . Reasonably expect coitus least monthly study period . 5 . In mutually monogamous relationship least 36 month duration ; 6 . Seeking avoid pregnancy next 12 month ; 7 . Willing use study device sole form contraception ; 8 . Willing accept risk pregnancy ; 9 . Normal PAP ASCUS negative high risk HPV test result within appropriate screen timeframe , unless consider risk ; 10 . Able willing comply study test , procedure , assessment tool followup ; 11 . Able willing provide document informed consent Authorization Release Protected Health Information ( PHI ) . 1 . Known suspected pregnancy ; risk pregnancy unprotected intercourse earlier current cycle 2 . Subject anticipate separation partner 1 cycle within next 12 month ; 3 . A previously insert IUD remove time LevoCept place ; 4 . History previous IUD complication , perforation , expulsion , infection ( pelvic inflammatory disease ) pregnancy IUD place . ; 5 . Injection hormonal contraceptive ( e.g. , DepoProvera ) within last 10 month ; 5.1 Must 2 normal menstrual cycle since last injection ; 6 . Planned use noncontraceptive estrogen , progesterone testosterone time 12 month study participation ; 7 . Postpartum , prior minimum 6 week complete uterine involution ; 8 . Exclusively breastfeed return menses ; Lactating woman exclude unless two normal menstrual period prior enrollment . 8.1 Must 2 normal spontaneous menstrual cycle since delivery 9 . Unexplained abnormal uterine bleeding ( suspicious serious condition ) , evaluation ; Immediately postseptic abortion puerperal sepsis ; 10 . Severely heavy painful menstrual bleeding ; 11 . Suspected known cervical , uterine ovarian cancer , unresolved clinically significant abnormal pap smear require evaluation treatment . 12 . Any history gestational trophoblastic disease without detectable elevate ßhCG level , relate malignant disease without intervene normal pregnancy ; 13 . Known anatomical abnormality uterine cavity may complicate IUD placement , : 13.1 Submucosal uterine leiomyoma 13.2 Asherman 's syndrome 13.3 Pedunculated polyp 13.4 Bicornuate uterus 13.5 Didelphus uterine septum 14 . Known anatomical abnormality cervix severe cervical stenosis , prior trachelectomy extensive conization , opinion investigator would prevent cervical dilation study device placement ; 15 . Current recent ( within last 3 month ) pelvic infection ( cervix , endometrium , fallopian tube ) , mucopurulent cervicitis ; 16 . High risk STDs ( e.g. , multiple sexual partner ) ; 17 . Known suspected HIV infection clinical AIDS ; 18 . Known intolerance allergy component LevoCept system ; include nickel , silicone tantalum ; 19 . Currently participate plan future participation research study investigational drug device course investigational study ; 20 . Subject LevoCept place previously 2 attempt placement ; 21 . Known suspected alcohol drug abuse within 12 month prior screen visit ; 22 . Any general health behavioral condition , opinion Investigator , could represent increase risk subject would render subject less likely provide need study information .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>contraception</keyword>
</DOC>